Abstract
The expression of the programmed cell death protein 1 (PD-1) is markedly increased in tumor-infiltrating lymphocytes, but its presence in bronchoalveolar lavage (BAL) fluid is less characterized. This prospective study quantified PD-1+ CD4+ and CD8+ T cells in BAL samples from 34 patients (14 lung cancer, 10 asthma, 10 interstitial lung disease [ILD]) using flow cytometry. The highest median proportions of PD-1+ T cells were found in ILD patients (CD4+: 83.1%; CD8+: 73.8%), followed by lung cancer (CD4+: 66.4%; CD8+: 77.1%) and asthma (CD4+: 61.3%; CD8+: 57.3%). A significant difference in PD-1+ CD4+ cells was observed between ILD and asthma patients ($p = 0.04$). PD-1 expression in lung cancer did not differ significantly from benign diseases, suggesting that the PD-1/PD-L1 pathway may play a significant role in ILD pathogenesis.
Introduction
Programmed cell death protein 1 (PD-1) is a critical immune checkpoint. While its role in the tumor microenvironment is well-established, its expression on T cells within the broader pulmonary environment—accessible via bronchoalveolar lavage (BAL)—is not fully understood. This study investigates whether BAL PD-1 expression can distinguish lung cancer from benign inflammatory conditions like asthma and interstitial lung disease (ILD), potentially serving as a diagnostic biomarker or providing insight into shared inflammatory pathways.
Methods
The study included 34 patients undergoing bronchoscopy at the Medical University of Vienna, categorized into lung cancer ($n=14$), asthma ($n=10$), and ILD ($n=10$) groups. BAL fluid was collected using 200 ml of saline. Flow cytometry quantified PD-1 (CD279) expression on CD4+ and CD8+ T cells. Additionally, differential cytology was performed to characterize the cellular landscape of the BAL fluid. For cancer patients, tumor PD-L1 expression (TPS/CPS) was correlated with BAL findings.
Results
Differential cytology across the three groups (Figure 1) established the baseline cellular composition of the BAL fluid, showing the distribution of macrophages, lymphocytes, and other cells.
The primary analysis revealed that high proportions of PD-1+ "exhausted" T cells are not unique to lung cancer. ILD patients exhibited the highest median proportion of PD-1+ CD4+ T cells (83.1%), which was significantly higher than in asthma patients (61.3%, $p = 0.04$). In lung cancer, the median proportion was 66.4%.
For CD8+ T cells, lung cancer patients showed the highest median expression (77.1%), followed by ILD (73.8%) and asthma (57.3%), though these differences lacked statistical significance (Figure 2). Notably, BAL PD-1 levels did not correlate with tumor PD-L1 expression, suggesting that the BAL fluid reflects a regional pulmonary immune state rather than the specific biology of the solid tumor.
Discussion
The elevated PD-1 expression in ILD patients suggests that the immune environment in fibrotic lung disease is highly regulated and potentially "exhausted," mirroring the tumor microenvironment. This supports the hypothesis that the PD-1/PD-L1 pathway may be involved in pulmonary fibrosis, possibly allowing fibroblasts to evade immune surveillance.
While BAL PD-1 levels do not currently serve as a standalone diagnostic tool for lung cancer due to overlap with benign conditions, the findings highlight the importance of the PD-1 pathway in ILD. Future research with larger, more homogeneous cohorts is warranted to explore the therapeutic potential of PD-1 blockade in fibrotic diseases and to determine if BAL immune profiles can predict responses to checkpoint inhibitors.
Summary updated